NCT00541476已完成不适用
Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Undergoing Symptomatic Treatment With Lyrica
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.0 个研究点目标入组 746 人开始时间: 2007年6月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 746
研究概览
简要总结
The purpose of this study is to obtain more data about efficacy and safety of the study drug Lyrica.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of peripheral or central neuropathic pain
排除标准
- •None. Patients recruited by physician decision. Patient's personal data are not collected.
研究者
相似试验
已完成
不适用
Clinical Study With Lyrica In Patients Suffering From EpilepsyNeuralgiaEpilepsyNCT00922987Pfizer's Upjohn has merged with Mylan to form Viatris Inc.286
已完成
4 期
Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).EpilepsyNCT00288639Pfizer's Upjohn has merged with Mylan to form Viatris Inc.98
已完成
3 期
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial EpilepsyEpilepsy, PartialNCT00280059Pfizer's Upjohn has merged with Mylan to form Viatris Inc.660
已完成
不适用
Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)NeuralgiaNCT01256593Pfizer's Upjohn has merged with Mylan to form Viatris Inc.3,827
已完成
不适用
Safety and Performance of a GLOBAL Mapping and Ablation Device for the Treatment of Atrial Fibrillation (GLOBAL-AF)Atrial FibrillationNCT02168972Kardium Inc.60